INTRODUCTION
Persons with Chronic Hepatitis C (CHC) infection exhibit rates of liver mortality that are between 17 and 36 times greater than the general population [1] [2] [3] [4] [5] [6] . A prerequisite to an effective public-health response, is a complete understanding of the factors driving this phenomenon. Although CHC is an established cause of liver failure and liver cancer, we cannot assume that all liver deaths occurring in the CHC infected population are de-facto attributable to CHC. To judge the CHC contribution, we need to uncover the benchmark mortality rate; in other words, the rate of liver mortality that this population would exhibit in the absence of CHC. This is a challenging task; CHC infection is inextricably linked to high rates of: injecting drug use (IDU) [7] [8] [9] , alcohol use disorders (AUDs) [9] [10] [11] [12] [13] [14] , psychiatric comorbidities [9, 11] and polysubstance abuse [15] . Epidemiologically, it is hard to disentangle liver mortality attributable to CHC, from liver mortality that might have occurred anyway given competing risk factors.
A potentially misprized benchmark group, overlooked until now, are spontaneous resolvers. The natural history of infection is such that, upon exposure to the virus, three-quarters of individuals develop persisting chronic infection that is clearable only through antiviral treatment [16] . But the remaining quarter resolve the infection spontaneously (i.e. of their own accord) within a matter of weeks to months [17] . Resolvers, by virtue of being exposed to HCV at all, are likely to be broadly similar to their chronic counterparts in terms of lifestyle exposures. In this sense then, resolvers may serve as a useful yardstick from which to assess the independent contribution of CHC. With these thoughts in mind, a joint research initiative between Denmark and Scotland was established. To our knowledge, we are the only two countries in the developed world: (i) with a national HCV diagnosis database capable of distinguishing persons diagnosed with HCV antibodies according to their chronic versus resolved infection status, and (ii) where those databases are linked routinely to subsequent mortality data. Using these unique data, our aim was to examine the extent to which liver mortality in persons with CHC, is indeed a CHC-related phenomenon.
METHODS

STUDY DESIGN AND SETTING:
We performed a record linkage analysis utilising HCV diagnosis, hospitalisation and mortality registers in two distinct settings -Denmark and Scotland. Both are Northern European countries with ~5.5 million inhabitants. The estimated prevalence of CHC infection is ~0.4% in Denmark [18] (equivalent to ~17,000 individuals) and ~0.8% in Scotland [19] (~39,000 individuals). In both settings, the principal transmission route is IDU [7, 20] . In Denmark, ~0.5% of persons living with CHC receive antiviral therapy each year [21] , whereas in Scotland, treatment uptake is higher at 2.5-3% [19] . Official population statistics on alcohol use and related sequalae suggest historically higher consumption levels in Denmark than in Scotland; albeit, differences have diminished over the last decade (see eFig.1).
DATA SOURCES:
Denmark: HCV infected patients were identified from the Danish HCV diagnosis database (known as DANVIR), comprising all persons tested for HCV in 14 of the 18 laboratories that perform such testing in Denmark [6] . DANVIR data include results and dates of HCV antibody tests (from 1991 onward) and HCV RNA tests (from 1995 onward).
Data on the vital status of all Danish citizens, including date of death or emigration, is stored by the Civil Registration
System [22] . The Danish National Registry of Causes of Death contains information on date and causes of death on all deceased Danish citizens [23] . The Danish National Patient Registry (DNPR), established in 1977, collects information on all non-psychiatric hospital admissions in Denmark, and since 1995, outpatient and emergency department visits moreover. Data linkage between DANVIR and: (i) the Civil Registration System; (ii) the Danish National Registry of Causes of Death; and (iii) the DNPR, was performed through deterministic matching of the unique 10-digit civil registration number assigned to all individuals in Denmark [22] .
Scotland: HCV infected individuals were identified through the Scottish HCV diagnosis database, which records all new anti-HCV positive diagnoses in Scotland from 1991 onwards [1] . Scotland also holds a national database for: (i) all general and acute inpatient/day case hospital admissions (known as the SMR-01 database); (ii) all mental health inpatient/day case admissions (known as the SMR-04 database); and (iii) all deaths [24] . The HCV diagnosis database was linked to these three registries through a two-step process. Using the full set of patient identifiers held on the HCV diagnosis (forename initial, surname soundex, date of birth, gender, postcode sector), an intermediary linkage to the Community Health Index (CHI) database was performed to obtain the "CHI number" (step 1). The CHI number is a unique individual-specific number allocated to every person upon registration with a general practitioner in Scotland; it functions as a master index for linkage between population registries in Scotland and is equivalent to the aforementioned Danish civil-registration number. Knowledge of the CHI number therefore enabled retrieval of each HCV diagnosed patient's records from the SMR-01, SMR-04, and mortality databases (step 2). These linkages were performed by Information Services Division Scotland, after approval from National Services Scotland Privacy Advisory 
EXPOSURE VARIABLES
The primary exposure variable was chronic versus spontaneous resolved HCV infection inferred from the first determinate HCV RNA test conducted following or simultaneous to the diagnosis of HCV antibodies. Specifically, a first test with a positive HCV RNA result was taken to indicate chronic infection, whilst a first test with a negative result was taken to indicate spontaneous resolution. In Scotland, trained data entry staff with access to full PCR test history apply this definition manually to all patient records. In contrast, for Denmark where all RNA tests are recorded and stored within DANVIR itself, this definition was applied electronically. We also characterised individuals in terms of IDU history. For Denmark, IDU was defined as inclusion in the Registry of Drug Abusers Undergoing Treatment and/or a record of one or more diagnoses suggesting IDU in the DNRP (Appendix A). For Scotland, a history of IDU was based on risk information disclosed by the patient at the time of the HCV test.
OUTCOME VARIABLE
Liver mortality was the primary outcome. This was defined using the underlying (i.e. primary) cause of death, specified by the followingICD-9 and ICD-10 codes: primary liver cancer (ICD-10 C22; ICD-9 155); alcoholic liver disease (ICD-10 K70;ICD-9 571.0-571.3); non-alcoholic liver disease (ICD-10 K71-77; ICD-9 570, 571.4-571.9, 572-573); viral hepatitis (ICD-10 B15-19; ICD-9 070); and sequelae of viral hepatitis (ICD-10 B94.2; R18; I850; ICD-9 456.0, 789.5).
STATISTICAL ANALYSIS:
To avoid breaching patient confidentiality safeguards, Danish and Scottish linkage data were analysed separately, by different authors (LO and HI), but according to a single standardised protocol. The main analysis was to determine the fraction of liver death in the CHC diagnosed population that is attributable to CHC (i.e. that would not have occurred if CHC had not been present). We further carried out an auxiliary analysis, and a one-way sensitivity analysis to support interpretation of the main analysis -as follows: hospitalisation for an acute instance of drug intoxication; 2) hospitalisation for an acute instance of alcohol intoxication;
and 3) hospitalisation for injury incurred through violence (although N.B, violence-related injury could not be assessed as a behavioural outcome in Denmark because this outcome is recorded in a separate registry that we did not have access to for this study [25] ).ICD codes were used to define all events; see eTable 1. We calculated the hazard ratio for each event, according to chronic infection versus spontaneous resolved infection, after adjustment for age group, gender and known history of IDU. were younger than those with chronic infection (on average, by 1.3-1.5 years), and were more commonly female; see Table 1 .
FOLLOW-UP TIME AND LIVER MORTALITY:
The total duration of follow-up in Denmark was 46,134 person-years; equating to a median per patient observation of resolvers were due to alcoholic liver disease (i.e. in >2/3 rds of instances), with a minimal contribution from liver cancer (<6%). A different picture was apparent for those with chronic infection; alcoholic liver disease was less frequently indicated (in <50% of deaths), whilst more than a fifth of liver mortality was attributed to hepatocellular carcinoma (21.5-21.6%).
MAIN ANALYSIS: FRACTION OF LIVER DEATH ATTRIBUTABLE TO CHC INFECTION
The TAF was 0.66 (95%:0.57-0.79) in Denmark and 0.55 (95%CI: 0.44-0.66) in Scotland-but it varied according to the age at death (see Fig.1 ). Table 3 .
SENSITIVITY ANALYSIS: ACCOUNTING FOR THE IMPACT OF ANTIVIRAL THERAPY
In Scotland, during the course of follow-up, 5059 individuals with CHC were treated with antiviral therapy and, 2436 attained SVR. We note that 94 spontaneous resolvers were also listed as having received a course of treatment during follow-up -we discuss this observation in our limitations section. When censoring follow-up time at SVR attainment, the TAF increased minimally to 0.59 (95% CI: 0.48-0.68); see eFig 4.
DISCUSSION PRINCIPAL FINDINGS:
Rates of liver mortality are high among persons with CHC [1] [2] [3] [4] [5] [6] . An effective public-health response to this phenomenon must reflect the causes behind these excess deaths. In this study, we use spontaneous resolvers as a benchmark group, to judge the independent contribution of CHC. Our findings indicate that in Scotland, 55% (95% CI:
44-66) of liver death among CHC-infected individuals can be attributed to the CHC exposure. In Denmark, this fraction is higher at 66% (95% CI: 55-78). On the one hand, these results support the consensus view -that the majority of liver death in this population is attributable to the CHC exposure. At the same time, they also show that a not insignificant portion of liver mortality appears to occur independently of infection; there are two immediate corollaries of this.
Firstly, although attempts to curtail liver mortality in this population rest mainly on the provision of antiviral therapy, antivirals alone may not be sufficient to eradicate the liver mortality problem. Secondly, if a baseline risk of liver disease among persons who acquire HCV exists, then we must ensure that this is fairly incorporated into modelling work. Existing cost-effectiveness [27] [28] [29] [30] , population forecasting [31] [32] [33] , and patient prognosis models [34] tend to assume negligible disease progression in the absence of chronic infection; this assumption will likely bias results in favour of treatment and may give rise to inflated drug costs.
VALIDITY OF USING SPONTANEOUS RESOLVERS AS A BENCHMARK GROUP
Using spontaneous resolvers as a control group to gauge the independent contribution of CHC is a novel idea.Resolvers, by virtue of having been exposed to HCV at all, are likely to be broadly similar to their chronic counterparts in terms of adverse health behaviours (behaviours that are otherwise difficult to measure precisely [35.36] but which may influence liver disease progression appreciably).This assumption of similarity betweeen chronics and resolvers in terms of adverse health behaviours is supported by studies examining the determinants of spontaneous resolution [37] [38] [39] [40] . We further performed an auxillary analysis to assess the ongoing risk of hospitalisation for acute alcohol intoxication, acute drug intoxication and hospitalisation for violence-related injury (i.e.admissions that reflect ongoing adverse health behaviors). We found similar admission risks according to infection status with the exception of a small increased risk of drug intoxication in Danish chronics versus Danish resolvers (HR 1.25; 95% CI: 1.06-1.49). However a limitation of this auxiliary analysis is that it only considers the relationship between infection status and extreme health behaviours.
In other words, the results may not generalise to moderately adverse-but harmful nonetheless -health behaviours.
Spontaneous resolvers differ from chronically infected persons demographically (are more commonly younger and of female gender [17] ), and genetically (in terms of single nucleotide polymorphisms in the vicinity of the IL28B gene [41] ). Our analyses are adjusted for age and gender, but not for any genetic differences between these two groups that may govern immune system response. This is an important limitation because it might undervalue the risk that CHC poses; recent studies have shown that among individuals with CHC, polymorphisms favouring spontaneous resolution may be associated with hepatic decompensation [42] . It is possible that these polymorphisms could hasten liver disease progression from other aetiologies [43] , meaning that paradoxically, individuals who spontaneously resolve HCV may be more susceptible (in a genetic sense) to liver disease, than those who progress to chronic infection. Nevertheless, the picture is very preliminary-the potential for bias here should be reviewed as new data emerges. A further implicit assumption of this analysis is that the duration for which spontaneous resolvers harbour viral RNA (median of 16.6
weeks [17] ) is sufficiently short to preclude the virus causing any significant liver damage. Very occasionally, spontaneous resolution occurs much later [44] , and in these instances, the potential for HCV-induced liver damage will be greater.
FURTHER LIMITATIONS AND CAVEATS
Our definition of spontaneous resolution is based on the very first PCR test result conducted after or at the time of antibody detection. This should offer a robust indication of chronic versus resolved infection given the established serological timeline of infection [45] . However, this definition has two caveats. First some individuals will have gone on clear their chronic infection through antiviral therapy during the course of follow-up. This switch from chronic to cleared chronic is not accounted for in our base case analysis, For two reasons though, this is unlikely to impact our results: (A) at the population level, the impact of antiviral therapy on liver mortality is known to have been minimal, owing in part to poor response rates and low uptake [5] ; and (B) in a sensitivity analysis where we excluded all persons known to have attained an SVR in Scotland, the TAF increased only marginally (by <5%; see eFig.4). Although, the same analysis was not performed for Denmark, we would expect an even slighter change here given lower treatment uptake rates, relative to Scotland. The second caveat is that some of our spontaneous resolvers will have been reinfected during follow-up and will have then developed chronicity through that re-infection event. When conducting our sensitivity analysis, we noticed that 94 (2%) Scottish resolvers had been treated with antiviral therapy; these cases will reflect such instances of reinfection. This misclassification of resolver status is a limitation of our analysis; nevertheless, it will apply to a small fraction of cases only. Regarding the generalisability of these data: whilst we calculated TAFs for two distinct North European countries and observed broadly similar results, we would not expect our findings to hold for all settings. In particular, we would anticipate a higher TAF overall in countries with an older infected population than Denmark and Scotland (and equally a lower TAF in countries with a younger infected population).
Further our TAFs are unlikely to generalise to settings where HCV transmission is not associated with adverse health behaviours (in the main, low and some middle income countries where transmission is driven by nonsocomial routes as opposed to injecting drug use). Another limitation is that ~25-40% of diagnosis records were excluded from our final samples (mainly due to insufficient identifiers and missing chronic infection status) -we cannot rule out the introduction of selection bias into our results as a result of these exclusions. A further potential bias to note is that a physician may be more inclined to attribute a death to liver disease if the deceased had CHC infection as opposed to spontaneously resolved infection -if this is the case, then our TAFs will be biased towards one. We should further make clear that this analysis only examines the impact of CHC on liver sequalea and does not address the impact of CHC on extrahepatic outcomes and pyschosocial manifestations. Finally, we did not use a consistent approach to determine injecting drug use history. In Denmark, IDU status was determined via a registry of drug abusers undergoing treatment, whereas in Scotland, IDU status is based on risk information disclosed to the physician at the time of the hepatitis C test. It is possible that the Danish definition (i.e. appearance on a drug abuse treatment register) will select out a more persistent subset of drug users that have been repeatedly exposed to HCV, and hence have a higher chance of chronicity. This might explain why an association between injecting drug use and chronic infection was observed for Denmark but not for Scotland (see Table 1 ).
CONSISTENCY WITH PREVIOUS WORK:
Our analysis suggests that a significant portion of liver mortality among CHC infected persons occurs independently of CHC infection. Previous work in resource-rich settings is in support of this, and points towards the non-CHCattributable death being a reflection of adverse health behaviours (AUDs in particular); as follows:
1. HCV infection is associated with a singular lifestyle profile, distinct from that of the general population [3, [7] [8] [9] [10] [11] [12] [13] [14] [15] ].
2. AUDs in particular are highly prevalent among persons with CHC [9] [10] [11] [12] [13] [14] which are in turn strongly associated with liver mortality [46] .
3. More than a third of Scottish CHC patients attending treatment services with liver cirrhosis, have reached this state as a direct consequence of heavy alcohol use [26] . Further, between 15 and 52% of liver deaths in this population are indicated directly, via the cause of death, to be a primary consequence of alcohol use. [5] .
Indeed in this analysis, alcoholic liver disease was listed as the primary cause of death for 45% and 48% of liver deaths among CHC infected persons in Scotland and Denmark, respectively (see eFig.3).Thus, it is already known that that many instances of liver cirrhosis and liver mortality are attributable to alcohol use -but that is not to say that alcohol was the exclusive cause and that CHC did not contribute in a "necessary but insufficient" way). In this respect our results lend a distinct advancement, insofar as they indicate an appreciable fraction of liver death would still have occured in the absence of CHC.
4. When HCV is introduced into cohorts with a stable lifestyle profile, rates of liver disease remain relatively low after 2-3 decades of infection [47] [48] [49] [50] .
5. Elevated mortality rates are also apparent in the siblings of HCV infected persons. These high rates mostly
reflect an excess number of unnatural and substance abuse-related deaths. An excess number of liver deaths, albeit, was not observed [51, 52] .
SUMMARY
Most instances of liver mortality among CHC infected persons can be attributed to CHC -all the same, an appreciable fraction of liver death appears to be independent of this exposure. This suggests that antiviral therapy will only be a partial solution to the problem of wayward liver mortality in this population. A full solution should entail more emphasis on tackling adverse health behaviours and the circumstances that give rise to them. Recent data highlights that behavioural interventions might be effective in the HCV infected population [53] ; but this historically has been (and so far still is) a neglected territory of research.
